Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synbiotic2 is a specific formulation of a synbiotic dietary supplement investigated for its effects on gut microbiota and weight management in obese patients undergoing a very-low-calorie ketogenic diet (VLCKD) followed by a low-calorie diet (LCD). It contains *Bifidobacterium animalis subsp. lactis* and prebiotics fiber. The supplement aims to modulate the gut microbiome, leading to an increase in beneficial bacteria such as short-chain fatty acid-producing bacteria (e.g., *Odoribacter* and *Lachnospira*) and anti-inflammatory mediators. This modulation is hypothesized to improve weight loss outcomes by ameliorating inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on synbiotic2.